215 related articles for article (PubMed ID: 22361589)
1. The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders.
Souayah N; Hasan A; Khan HM; Yacoub HA; Jafri M
J Clin Neuromuscul Dis; 2011 Jun; 12 Suppl 4():S1-10. PubMed ID: 22361589
[TBL] [Abstract][Full Text] [Related]
2. Safety of liquid intravenous immunoglobulin for neuroimmunologic disorders in the home setting: a retrospective analysis of 1085 infusions.
Rigas M; Tandan R; Sterling RJ
J Clin Neuromuscul Dis; 2008 Dec; 10(2):52-5. PubMed ID: 19169090
[TBL] [Abstract][Full Text] [Related]
3. Not all intravenous immunoglobulin preparations are equally well tolerated.
Feldmeyer L; Benden C; Haile SR; Boehler A; Speich R; French LE; Hofbauer GF
Acta Derm Venereol; 2010 Sep; 90(5):494-7. PubMed ID: 20814625
[TBL] [Abstract][Full Text] [Related]
4. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
5. A Retrospective Analysis of the Safety Profile of Intravenous Immunoglobulin in 1176 Patients Receiving Home Infusion Therapy.
Souayah N; Pahwa A; Burawski L; Opila T; Sander HW
J Clin Neuromuscul Dis; 2018 Jun; 19(4):181-195. PubMed ID: 29794573
[TBL] [Abstract][Full Text] [Related]
6. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content.
Manlhiot C; Tyrrell PN; Liang L; Atkinson AR; Lau W; Feldman BM
Pediatrics; 2008 Mar; 121(3):e626-30. PubMed ID: 18299304
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature.
Marie I; Maurey G; Hervé F; Hellot MF; Levesque H
Br J Dermatol; 2006 Oct; 155(4):714-21. PubMed ID: 16965420
[TBL] [Abstract][Full Text] [Related]
8. Safety of intravenous immunoglobulin (IVIG) therapy.
Katz U; Achiron A; Sherer Y; Shoenfeld Y
Autoimmun Rev; 2007 Mar; 6(4):257-9. PubMed ID: 17317619
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
[TBL] [Abstract][Full Text] [Related]
10. Intravenous immunoglobulin administration: an evaluation of vital sign monitoring.
Camp-Sorrell D; Wujcik D
Oncol Nurs Forum; 1994 Apr; 21(3):531-5. PubMed ID: 8052549
[TBL] [Abstract][Full Text] [Related]
11. Side effects of intravenous immunoglobulins in neurological autoimmune disorders--a prospective study.
Stangel M; Kiefer R; Pette M; Smolka MN; Marx P; Gold R
J Neurol; 2003 Jul; 250(7):818-21. PubMed ID: 12883923
[TBL] [Abstract][Full Text] [Related]
12. A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG.
Lozano-Blasco J; Martín-Mateos MA; Alsina L; Domínguez O; Giner MT; Piquer M; Alvaro M; Plaza AM
Allergol Immunopathol (Madr); 2014; 42(2):136-41. PubMed ID: 23253680
[TBL] [Abstract][Full Text] [Related]
13. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile.
Dalakas MC
Pharmacol Ther; 2004 Jun; 102(3):177-93. PubMed ID: 15246245
[TBL] [Abstract][Full Text] [Related]
14. Significant dermatological side effects of intravenous immunoglobulin.
Hurelbrink CB; Spies JM; Yiannikas C
J Clin Neurosci; 2013 Aug; 20(8):1114-6. PubMed ID: 23659929
[TBL] [Abstract][Full Text] [Related]
15. Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long-term outcome.
Nosadini M; Mohammad SS; Suppiej A; Sartori S; Dale RC;
Dev Med Child Neurol; 2016 Nov; 58(11):1180-1192. PubMed ID: 27242065
[TBL] [Abstract][Full Text] [Related]
16. Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy.
Gerstenblith MR; Antony AK; Junkins-Hopkins JM; Abuav R
J Am Acad Dermatol; 2012 Feb; 66(2):312-6. PubMed ID: 21601310
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulin treatment in autoimmune neurological disorders--effects on quality of life.
Padua L; Sabatelli M; Evoli A; Pazzaglia C; Tonali P
Hum Immunol; 2005 Apr; 66(4):417-21. PubMed ID: 15866706
[TBL] [Abstract][Full Text] [Related]
18. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature.
Vecchietti G; Kerl K; Prins C; Kaya G; Saurat JH; French LE
Arch Dermatol; 2006 Feb; 142(2):213-7. PubMed ID: 16490849
[TBL] [Abstract][Full Text] [Related]
19. Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases.
Mignogna MD; Fortuna G; Leuci S; Ruoppo E; Adamo D; Fedele S
Clin Exp Dermatol; 2009 Mar; 34(2):145-50. PubMed ID: 19187294
[TBL] [Abstract][Full Text] [Related]
20. Acute ST elevation myocardial infarction during intravenous immunoglobulin infusion.
Barsheshet A; Marai I; Appel S; Zimlichman E
Ann N Y Acad Sci; 2007 Sep; 1110():315-8. PubMed ID: 17911446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
